Advantages of using estimated depression-free days for evaluating treatment efficacy
- PMID: 20123821
- PMCID: PMC3049453
- DOI: 10.1176/ps.2010.61.2.160
Advantages of using estimated depression-free days for evaluating treatment efficacy
Abstract
Objective: Several common methods for measuring treatment response present a snapshot of depression symptoms. The construct of estimated depression-free days (DFDs) simultaneously captures treatment outcome and estimates the patient's experience of depression over time. The study compared this measure with traditional measures used in depression treatment research.
Methods: This secondary data analysis was based on data from the Improving Mood-Promoting Access to Collaborative Treatment trial, a multisite depression treatment study conducted in 18 primary care clinics in five states and representing eight health care systems. The sample of older adults (N=906) had been randomly assigned to receive collaborative care for depression. Participants were aged 60 or older and met criteria for major depressive disorder, dysthymia, or both. Exclusion criteria included severe cognitive impairment, active substance abuse, active suicidal behavior, severe mental illness, and active treatment from a psychiatrist. The Patient Health Questionnaire (PHQ-9) and the Hopkins Symptom Checklist (HSCL-20) were used as outcome measures at four assessment points (baseline, three months, six months, and 12 months). Outcomes were computed for relative change, standardized differences, the proportion of improvement in depression, and DFDs.
Results: Using four assessment points improved the agreement between DFDs and the course of symptom change between pre- and posttest measures.
Conclusions: The DFD is a valid measure for estimating treatment outcomes that reflects the course of symptom change over time. When multiple assessments were conducted between the pre- and posttest periods, DFDs incorporated additional data yet remained easily interpreted. The DFD should be considered for reporting outcomes in depression research.
References
-
- Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Journal of Clinical Psychiatry. 2003;64:321–330. - PubMed
-
- Cohen J. A power primer. Psychological Bulletin. 1992;112:155–159. - PubMed
-
- Riso LP, Thase ME, Howland RH, et al. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. Journal of Affective Disorders. 1997;43:131–142. - PubMed
-
- Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry. 1998;55:645–651. - PubMed
-
- Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. American Journal of Psychiatry. 2006;163:1379–1387. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous